Stereotaxis (STXS) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$30.1M

Revenue (quarter)

$7.7M

Revenue growth (year over year)

−12.82%

Gross profit (trailing twelve months)

$16.7M

Gross margin

55.57%

Net income (trailing twelve months)

−$22.3M

Net income (quarter)

−$4.5M

Net income growth (year over year)

−16.78%

Net margin

−74.24%

Return on equity

−249.16%

EPS (trailing twelve months)

−$0.24

Book value per share

$0.18

P/E (trailing twelve months)

—

Price to book

6.02

Debt to assets

68.56%

Payout ratio

—

Dividend yield

—

Company profile

Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems, Disposables, Royalty, and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.

• Is Stereotaxis (STXS) profitable?

  No. Stereotaxis reported a net loss of $22.3M over the trailing twelve months.

• How much revenue does Stereotaxis (STXS) make?

  Stereotaxis generated $30.1M in revenue over the trailing twelve months, down 12.82% year over year.

• How do I buy stock in Stereotaxis (STXS)?

  STXS trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.